A Study to Determine Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® in Schizophrenia Patients

NCT03751488 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizo Affective Disorder
Schizophrenia
Schizoaffective Disorder

Interventions

DRUG: LY03010
DRUG: Invega Sustenna 156 MG in 1 ML Prefilled Syringe

Sponsor

Luye Pharma Group Ltd.